Valuation: ARS Pharmaceuticals, Inc.

Capitalization 794M 679M 626M 591M 1.1B 74.38B 1.13B 7.33B 2.88B 35.52B 2.98B 2.92B 127B P/E ratio 2026 *
-5.35x
P/E ratio 2027 * -12.9x
Enterprise value 794M 679M 626M 591M 1.1B 74.38B 1.13B 7.33B 2.88B 35.52B 2.98B 2.92B 127B EV / Sales 2026 *
4.96x
EV / Sales 2027 * 2.75x
Free-Float
76.7%
Yield 2026 *
-
Yield 2027 * -
Mar. 27 ARS Pharmaceuticals Says US FDA Approves Label Update Removing Age Restriction in Neffy Dose for Children MT
Mar. 27 ARS Gets FDA Approval to Remove Age Requirement for Allergic-Reaction Nasal Spray DJ
Mar. 27 Ars Pharmaceuticals receives FDA approval to remove age requirement from Neffy 1 mg (epinephrine nasal spray) label RE
Mar. 27 ARS Pharmaceuticals Inc Receives FDA Approval To Remove Age Requirement From Neffy 1 Mg Epinephrine Nasal Spray Label CI
Mar. 09 ARS Pharmaceuticals, Inc., Q4 2025 Earnings Call, Mar 09, 2026
Mar. 09 ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Mar. 09 ARS Pharmaceuticals reports fourth quarter and full year 2025 financial results RE
Mar. 09 ARS Pharmaceuticals Reports Q4 Net Loss MT
Mar. 09 Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q4 Revenue $28.1M MT
Mar. 09 Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Net Loss $0.42 a Share, vs. FactSet Est of $0.39 Loss MT
Feb. 10 Ars Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on Neffy®? (Epinephrine Nasal Spray) At 2026 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting CI
Feb. 02 ARS Pharmaceuticals Announces EURneffy 1 Mg (Adrenaline Nasal Spray) Recommended For Approval In The EU For Emergency Treatment Of Type 1 Allergic Reactions In Children Weighing 15 Kg To Less Than 30 Kg CI
Feb. 02 ARS Pharmaceuticals Secures EMA Backing to Expand EURneffy Nasal Spray for Children With Anaphylaxis MT
1 day-0.62%
1 week-4.65%
Current month-0.37%
1 month-4.65%
3 months-29.27%
6 months-26.81%
Current year-31.33%
1 week 7.97
Extreme 7.974
8.56
1 month 7.2
Extreme 7.2
9.11
Current year 7.2
Extreme 7.2
13.15
1 year 6.66
Extreme 6.66
18.9
3 years 2.55
Extreme 2.55
18.9
5 years 2.55
Extreme 2.55
18.9
10 years 2.55
Extreme 2.55
18.9
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 57 2018-08-31
Chief Tech/Sci/R&D Officer - 2015-08-04
Chief Executive Officer 60 2018-08-31
Director TitleAgeSince
Director/Board Member 60 2015-08-04
Chairman 56 2022-11-07
Director/Board Member 55 2021-07-31
Change 5d. change 1-year change 3-years change Capi.($)
-0.62%-4.65%-43.06%+30.93% 799M
-1.06%+0.27%+26.92%+147.78% 841B
-0.21%-1.25%+56.83%+43.25% 574B
-0.71%-0.11%+17.95%+26.91% 368B
-0.35%-0.75%+29.45%+14.12% 320B
-1.59%-2.14%+49.76%+26.78% 318B
-1.05%-0.58%+51.74%+3.95% 300B
-0.94%-2.09%+40.11%+38.47% 295B
-0.34%+2.12%+22.32%+39.13% 189B
+0.03%-0.78%+34.16%+66.96% 173B
Average -0.57%-0.65%+28.62%+43.83% 337.87B
Weighted average by Cap. -0.47%-0.42%+36.87%+60.24%

Financials

2026 *2027 *
Net sales 160M 137M 126M 119M 221M 15B 227M 1.48B 581M 7.16B 601M 588M 25.58B 289M 247M 227M 215M 399M 27.04B 409M 2.66B 1.05B 12.91B 1.08B 1.06B 46.13B
Net income -149M -127M -118M -111M -206M -13.97B -211M -1.38B -541M -6.67B -560M -548M -23.83B -62.99M -53.81M -49.61M -46.82M -87M -5.9B -89.21M -581M -228M -2.82B -236M -231M -10.06B
Net Debt - -
Logo ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Employees
161
Date Price Change Volume
26-04-13 8.000 $ -0.62% 854,389
26-04-10 8.050 $ -2.66% 722,376
26-04-09 8.270 $ +0.98% 2,094,934
26-04-08 8.190 $ +0.49% 1,831,086
26-04-07 8.150 $ -2.86% 1,145,962
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.000USD
Average target price
26.71USD
Spread / Average Target
+233.93%

Quarterly revenue - Rate of surprise